A Phase 1 Study to Assess the Relative PK and Tissue Distribution of Guselkumab and Risankizumab in Healthy Participants and Patients With Psoriatic Arthritis
Latest Information Update: 28 Jul 2022
At a glance
- Drugs Guselkumab (Primary) ; Risankizumab (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Pharmacokinetics
- 22 Jul 2022 Status changed from recruiting to discontinued due to unanticipated feasibility constraints.
- 29 Mar 2022 Protocol was amended to add one more treatment arm (Part 3: PsA Participants-Separate Administration).
- 29 Mar 2022 Planned number of patients changed from 40 to 50.